For treatment of the following serious infections caused by or, most likely, caused by microorganisms sensitive to cefotaxime:​

• Bacterial pneumonia (cefotaxime does not affect bacteria that​ cause atypical pneumonia, or other bacterial strains that​ can cause atypical pneumonia, including P. aeruginosa – see section “Pharmacodynamics”).

• Complicated infections of the kidneys and upper urinary tract.

• Serious skin and soft tissue infections.

• Infections of sex organs caused by gonococci, especially when the use of penicillin has turned out to be ineffective or unsuitable.

• Intra-abdominal infections (including peritonitis): in the treatment of intra-abdominal infections, cefotaxime shall be used in combination with the antibiotic effective against anaerobic microorganisms.

• Acute bacterial meningitis (especially caused by H. Influenzae , N. Meningitis , S. pneumonia , E. coli , Klebsiella spp .).

• Lyme disease, or Lyme borreliosis (in particular stages 2 and 3).

• Bacteremias associated with or likely associated with one of the listed infections (if infection is caused by gram-negative bacteria, treatment shall include combination with another appropriate antibiotic).

• Endocarditis (if infection is caused by gram-negative bacteria, treatment shall include combination with another appropriate antibiotic).

For perioperative prevention of infectious complications (before/after) surgical operations, particularly colon and rectum surgeries (colorectal surgery), gastrointestinal surgery, prostate, genitourinary, obstetric and gynecological surgeries in patients with the evident risk of postoperative infections).

The official recommendations for the proper antibiotic use shall be observed.